These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21639)

  • 1. Hydroxylation of 5,5-diphenylhydantoin (phenytoin) by dog liver microsomes.
    Butler TC; Dudley KH; Mitchell GN; Johnson D
    Arch Int Pharmacodyn Ther; 1977 Jul; 228(1):4-9. PubMed ID: 21639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of the metabolism of 5,5-diphenylhydantoin relating principally to the stereoselectivity of the hydroxylation reactions in man and the dog.
    Butler TC; Dudley KH; Johnson D; Roberts SB
    J Pharmacol Exp Ther; 1976 Oct; 199(1):82-92. PubMed ID: 978486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreases in phenytoin hydroxylation activities catalyzed by liver microsomal cytochrome P450 enzymes in phenytoin-treated rats.
    Yamazaki H; Komatsu T; Takemoto K; Saeki M; Minami Y; Kawaguchi Y; Shimada N; Nakajima M; Yokoi T
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):427-34. PubMed ID: 11259327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation.
    Munns AJ; De Voss JJ; Hooper WD; Dickinson RG; Gillam EM
    Chem Res Toxicol; 1997 Sep; 10(9):1049-58. PubMed ID: 9305589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex differences in rats in the metabolism of phenytoin to 5-(3,4-dihydroxyphenyl)-5-phenylhydantoin.
    Billings RE
    J Pharmacol Exp Ther; 1983 Jun; 225(3):630-6. PubMed ID: 6864524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for an arene oxide-NIH shift pathway in the metabolic conversion of phenytoin to 5-(4-hydroxyphenyl)-5-phenylhydantoin in the rat and in man.
    Claesen M; Moustafa MA; Adline J; Vandervorst D; Poupaert JH
    Drug Metab Dispos; 1982; 10(6):667-71. PubMed ID: 6130920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereoselective inhibition of diphenylhydantoin metabolism by p-hydroxyphenyl-phenylhydantoin enantiomers in rats.
    Huang JD; Hsieh CY
    Chirality; 1991; 3(6):454-9. PubMed ID: 1812955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic and spectral studies of type I and type II compounds with rat hepatic microsomes in the presence of the major metabolite of diphenylhydantoin.
    Stavchansky SA; Kostenbauder HB; Lubawy WC
    Drug Metab Dispos; 1975; 3(6):557-64. PubMed ID: 1233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenytoin metabolism in mice.
    Chow SA; Fischer LJ
    Drug Metab Dispos; 1982; 10(2):156-60. PubMed ID: 6124402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenytoin metabolism to 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH) in man, cat and rat in vitro and in vivo, and susceptibility to phenytoin-induced gingival overgrowth.
    Kamali F; Ball DE; McLaughlin WS; Seymour RA
    J Periodontal Res; 1999 Apr; 34(3):145-53. PubMed ID: 10384402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absolute configuration of (+)-5-(o-hydroxyphenyl)-5-phenylhydantoin, the major metabolite of 5,5-diphenylhydantoin in the dog.
    Maguire JH; Butler TC; Dudley KH
    J Med Chem; 1978 Dec; 21(12):1294-7. PubMed ID: 722736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for an arene-3,4-oxide as a metabolic intermediate in the meta- and para-hydroxylation of phenytoin in the dog.
    Moustafa MA; Claesen M; Adline J; Vandervorst D; Poupaert JH
    Drug Metab Dispos; 1983; 11(6):574-80. PubMed ID: 6140142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans.
    Fritz S; Lindner W; Roots I; Frey BM; Küpfer A
    J Pharmacol Exp Ther; 1987 May; 241(2):615-22. PubMed ID: 3572817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on 5,5-diphenylhydantoin irreversible binding to rat liver microsomal proteins.
    Pantarotto C; Arboix M; Sezzano P; Abbruzzi R
    Biochem Pharmacol; 1982 Apr; 31(8):1501-7. PubMed ID: 7092941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies by biointeraction chromatography of binding by phenytoin metabolites to human serum albumin.
    Ohnmacht CM; Chen S; Tong Z; Hage DS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 May; 836(1-2):83-91. PubMed ID: 16621742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between phenytoin, 5-(p-hydroxyphenyl)-5-phenylhydantoin and valproate in the rat.
    O'Leary TD; Sansom LN
    J Pharmacol Exp Ther; 1981 Mar; 216(3):613-6. PubMed ID: 6782238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoniazid-induced inhibition in the biotransformation of [14C] diphenylhydantoin in rat.
    Buttar HS
    Res Commun Chem Pathol Pharmacol; 1977 Sep; 18(1):35-57. PubMed ID: 905633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4.
    Komatsu T; Yamazaki H; Asahi S; Gillam EM; Guengerich FP; Nakajima M; Yokoi T
    Drug Metab Dispos; 2000 Nov; 28(11):1361-8. PubMed ID: 11038165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
    Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
    Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous determination of p-hydroxylated and dihydrodiol metabolites of phenytoin in urine by high-performance liquid chromatography.
    Szabo GK; Pylilo RJ; Davoudi H; Browne TR
    J Chromatogr; 1990 Dec; 535(1-2):279-85. PubMed ID: 2089057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.